Pruebas de vaginitis aeróbica (VA) ahora disponibles en BioReference Laboratories

National launch of aerobic vaginitis (AV) testing coincides with National Women’s Health Week

Elmwood Park, NJ, 17 de mayo de 2019 — BioReference Laboratories, Inc., an OPKO Health company, along with its specialty women’s health division, GenPath, today announces the launch of new testing for aerobic vaginitis (AV).

AV is a vaginal infection caused by the overgrowth of aerobic bacteria that triggers an inflammatory response. Women affected by AV experience vaginal discharge with a foul odor, burning and itching. While AV is a separate infection from bacterial vaginosis (BV), AV commonly co-occurs with BV in 36.9% of vaginal discomfort cases. AV and BV, while similar, require different treatment regimes. If untreated, complications of AV include an increased risk for contracting sexually transmitted infections, pelvic inflammatory disease, infertility, premature labor, preterm delivery and premature rupture of membranes.

“Many patients with signs and symptoms of aerobic vaginitis are incorrectly diagnosed with other vaginal conditions; therefore, it is important that they receive more accurate diagnoses,” said James Weisberger, M.D., Chief Medical Officer of BioReference Laboratories. “The availability of laboratory testing for aerobic vaginitis allows us to support healthcare providers and their patients by more accurately assessing the vaginal microbiome, leading to more targeted treatment.”

This announcement of new testing for AV coincides with the 20th Annual National Women’s Health Week 2019, and serves as a reminder for women to make their health a priority and build positive health habits for life.

“With the addition of aerobic vaginitis testing to our already robust test menu for women’s health, BioReference is reaffirming our commitment to patients affected by emerging conditions,” said Geoff Monk, President of BioReference Laboratories. “AV awareness is relatively new to the medical community and we’re pleased to be able to offer diagnostics in disease areas not offered at most clinical laboratories.”

AV testing is available at BioReference through its specialty women’s health division, GenPath, which provides testing in the areas of genetics, reproductive and sexual health, maternal fetal medicine, oncology and urology. Testing for AV is not yet available in New York State, but is available outside of New York.

Para obtener más información, visite www.bioreference.com y www.genpath.com.   

For more information about National Women’s Health Week, visit https://www.womenshealth.gov/nwhw

Información acerca de BioReference Laboratories, Inc.
BioReference proporciona pruebas integrales a médicos, clínicas, hospitales, empleadores, unidades del gobierno, instituciones correccionales y centros médicos. La compañía trabaja en red con los cinco planes de salud más grandes de Estados Unidos, dirige una red de 11 laboratorios y está respaldada por un personal médico de más de 160 MD, PhD y otros clínicos y científicos de nivel profesional. Con una posición líder en las áreas de genética, salud de la mujer, medicina materno-fetal, oncología y urología, BioReference y sus laboratorios especializados, GenPath y GeneDx, están marcando el progreso en la medicina moderna. Para obtener más información, visite www.bioreference.com.

Información acerca de OPKO Health, Inc.
OPKO Health es una compañía de atención médica diversificada. In diagnostics, its BioReference Laboratories is the nation’s third largest clinical laboratory; GeneDx is a rapidly growing genetic testing business; the 4Kscore® prostate cancer test is used to confirm an elevated PSA to help decide about next steps such as prostate biopsy; Claros® 1 is a point-of-care diagnostics platform with a total PSA test approved by the FDA and testosterone as the most advanced test in development.  In our pharmaceutical pipeline, RAYALDEE is our first pharmaceutical product to be marketed.  OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity recently reported positive data from a Phase 2 clinical trial.  It’s among a new class of GLP-1/glucagon receptor dual agonists.  OPK88004, a SARM (selective androgen receptor modulator) is currently being studied for various potential indications.  The Company’s most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, is in Phase 3 trials, and is partnered with Pfizer.  OPKO also has research, development, production and distribution facilities abroad.  More information is available at www.opko.com

Advertencia respecto de declaraciones con perspectivas de futuro
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements about expectations for BioReference, our diagnostic testing services and their benefits, and our ability to launch new tests, as well as other non-historical statements about our expectations, beliefs or intentions. Muchos factores podrían hacer que nuestras actividades o resultados reales difieran sustancialmente de las actividades y resultados anticipados en las declaraciones con perspectivas de futuro. Estos factores incluyen aquellos descritos en los informes anuales de OPKO Health, Inc. Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission. Las declaraciones con perspectivas de futuro también pueden verse afectadas de manera adversa por factores generales del mercado, desarrollo de productos de la competencia, disponibilidad de productos, normas y leyes federales y estatales, el proceso regulatorio de nuevos productos e indicaciones, problemas de fabricación que puedan surgir, posiciones de patentes y litigios, entre otros factores. Las proyecciones que contiene este comunicado de prensa solo expresan la situación a la fecha en que se realizaron, y no asumimos obligación alguna de actualizar las proyecciones. Tenemos la intención de que todas las declaraciones con perspectivas de futuro estén sujetas a las disposiciones de puerto seguro de la ley PSLRA.

Natalie Cummins

BioReference Laboratories

8002295227

media@bioreference.com

Powered by Translations.com GlobalLink OneLink Software